Printer Friendly

Ionis submits Inotersen MAA with EMA for hereditary TTR amyloidosis.

M2 EQUITYBITES-November 6, 2017-Ionis submits Inotersen MAA with EMA for hereditary TTR amyloidosis


Drug discovery company Ionis Pharmaceuticals Inc (NASDAQ:IONS) said on Friday that it has filed its marketing authorisation application (MAA) with the European Medicines Agency (EMA) for inotersen for patients suffering from hereditary TTR amyloidosis (hATTR), a severe, rare and fatal disease.

Based on the company's phase 3 NEURO-TTR study in patients with hereditary TTR amyloidosis (hATTR), the MAA for inotersen will be reviewed under the EMA's Accelerated Assessment programme, which is intended to expedite access to drugs that the EMA considers to be of major therapeutic interest.

The company stated Inotersen is an antisense drug designed to reduce the production of transthyretin, or TTR, to treat patients with TTR amyloidosis (ATTR). TTR builds up as fibrils in tissues and as the TTR protein fibrils enlarge, more tissue damage occurs and the disease worsens, resulting in poor quality of life and eventually death.

Under the Phase 3 NEURO-TTR study in patients with polyneuropathy due to hereditary TTR amyloidosis (hATTR), the company identified two key safety issues: the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) and the modified Neuropathy Impairment Score +7 (mNIS+7) at both eight and 15 months of treatment. Enhanced monitoring was implemented during the study to support early detection and management of these issues.

According to the company, the overall mortality rate in the NEURO-TTR study was 2.9% and was lower than mortality rates reported in other studies in hATTR patients.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 6, 2017
Previous Article:First BancTrust reports reduced earnings for Q3 2017 year over year and dividend of USD0.11 per share.
Next Article:Alaska Air Group announces dividend of USD0.30 per share for quarter.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters